

**REMARKS****AMENDMENTS TO THE SPECIFICATION**

The Example section beginning on page 371, line 5 and continuing to page 506 of the substitute specification, submitted with Applicants January 5, 2005 Reply, was amended to correct typographical errors in the numbering of the Examples. Specifically, the numbering of all of the Examples residing subsequent to Example 9 was corrected to be in correct numerical order beginning with changing "Example 6" to "Example 10" and continuing to the end of the substitute specification. No new matter has been added.

JUN. 7. 2005 8:59AM BMS PATENT DEPT

NO. 3861 P. 127  
CASE D0072 NP

If any small matter should remain outstanding after the Patent Examiner has had an opportunity to review the above Remarks, the Patent Examiner is respectfully requested to telephone the undersigned attorney in order to resolve these matters.

Although it is believed no fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880 in the name of the Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-3575

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: June 7, 2005